A carregar...
Precision medicine becomes reality—tumor type-agnostic therapy
Precision medicine just witnessed two breakthroughs in oncology in 2017. Pembrolizumab (Keytruda), Merck’s anti-programmed cell death-1 (PD-1) monoclonal antibody (mAb), received accelerated approval in May 2017 by the US Food and Drug Administration for the treatment of adult and pediatric patients...
Na minha lista:
| Publicado no: | Cancer Commun (Lond) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5953403/ https://ncbi.nlm.nih.gov/pubmed/29764494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-018-0274-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|